Clinical appraisal of fosfomycin in the era of antimicrobial resistance

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7355-7361

  Sastry, Sangeeta ^a   Clarke, Lloyd G ^a   Alrowais, Hind ^a   Querry, Ashley M ^a   Shutt, Kathleen A ^a   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ABDOMINAL CRAMP; ADULT; ADVERSE OUTCOME; AGED; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASYMPTOMATIC BACTERIURIA; BACTERIUM ISOLATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE SURVEILLANCE; DRUG INDICATION; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RECURRENT INFECTION; SINGLE DRUG DOSE; TERTIARY CARE CENTER; TREATMENT INDICATION; URINALYSIS; URINARY TRACT INFECTION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; HOSPITAL PATIENT; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOSFOMYCIN; HUMANS; INPATIENTS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84954498748     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01071-15     Document Type: Article

References (25)

1. Foxman B. 2002. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(Suppl 1A):5S-13S.
2. Foxman B. 2010. The epidemiology of urinary tract infection. Nat Rev Urol 7:653-660. http://dx.doi.org/10.1038/nrurol.2010.190.
3. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. 2012. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 56:2181-2183. http://dx.doi.org/10.1128/AAC.06060-11.
4. Michalopoulos AS, Livaditis IG, Gougoutas V. 2011. The revival of fosfomycin. Int J Infect Dis 15:e732-e739. http://dx.doi.org/10.1016/j.ijid.2011.07.007.
5. Johnson JR, Drawz SM, Porter S, Kuskowski MA. 2013. Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and coresistance phenotype among recent Escherichia coli isolates from U.S. veterans. Antimicrob Agents Chemother 57:4856-4860. http://dx.doi.org/10.1128/AAC.00650-13.
6. Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C, Navarro-Mari JM, Gutierrez-Fernandez J. 2014. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control 42:1033-1038. http://dx.doi.org/10.1016/j.ajic.2014.06.013.
7. KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 54: 526-529. http://dx.doi.org/10.1128/AAC.01235-09.
8. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. 2012. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67:255-268. http://dx.doi.org/10.1093/jac/dkr466.
9. Karlowsky JA, Denisuik AJ, Lagace-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. 2014. In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARDsurveillance study. Antimicrob Agents Chemother 58:1252-1256. http://dx.doi.org/10.1128/AAC.02399-13.
10. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103-e120. http://dx.doi.org/10.1093/cid/ciq257.
11. Centers for Disease Control and Prevention. 2015. Urinary tract infection (catheter-associated urinary tract infection [CAUTI] and non-catheter-associated urinary tract infection [UTI]) and (other urinary system infection [USI]) events. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/nhsn/PDFs/pscManual/7pscCAUTIcurrent.pdf.
12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377-381. http://dx.doi.org/10.1016/j.jbi.2008.08.010.
14. van Duin D, Cober E, Richter SS, Perez F, Kalayjian RC, Salata RA, Evans S, Fowler VG, Jr, Kaye KS, Bonomo RA. 2015. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70:1203-1211.
15. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791-797. http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00007.
17. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. 2014. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 43:52-59. http://dx.doi.org/10.1016/j.ijantimicag.2013.09.010.
18. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrugresistant organisms. Antimicrob Agents Chemother 56:5744-5748. http://dx.doi.org/10.1128/AAC.00402-12.
19. Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S. 2010. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 65:1862-1877. http://dx.doi.org/10.1093/jac/dkq237.
20. Moroni M. 1987. Monuril in lower uncomplicated urinary tract infections in adults. Eur Urol 13(Suppl 1):S101-S104.
21. Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, Yang B, Niu YJ, Wang Y, Shi BK, Yang WM, Zhao XK, Gao XF, Chen M. 2013. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open 3:e004157. http://dx.doi.org/10.1136/bmjopen -2013-004157.
22. Castañeda-García A, Blázquez J, Rodríguez-Rojas A. 2013. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics 2:217-236. http://dx.doi.org/10.3390/antibiotics2020217.
23. Ho PL, Chan J, Lo WU, Lai EL, Cheung YY, Lau TC, Chow KH. 2013. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J Med Microbiol 62:1707-1713. http://dx.doi.org/10.1099/jmm.0.062653-0.
24. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. 2010. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 54:3061-3064. http://dx.doi.org/10.1128/AAC.01834-09.
25. Rodriguez A, Gallego A, Olay T, Mata JM. 1977. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy 23(Suppl 1):247-258.